The efficacy and safety of coenzyme Q10 in Parkinson’s disease: a meta-analysis of randomized controlled trials

Zhu, Zhenguo; Sun, Miao-Xuan; Zhang, Wanli; Wang, Wenwen; Jin, Yimei; Xie, Chenglong

doi:10.1007/s10072-016-2757-9

Cited by 74 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, a meta‐analysis that evaluated CoQ10 effects in Parkinson's disease found that treatment with 1,200 mg/day, and even 2,400 mg/day, was safe and well tolerated. In fact, there was no significant difference of adverse events between CoQ10 and placebo (Zhu et al., ). It has to be noted that plasma levels reached a plateau at 2,400 mg/day and did not increase further at 3,000 mg/day (Shults, Flint Beal, Song, & Fontaine, ).…”

Section: Coq10 Supplementationmentioning

confidence: 99%

Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges

Arenas-Jal

Suñé-Negre

García-Montoya

2020

Comp Rev Food Sci Food Safe

102

View full text Add to dashboard Cite

World population growth and aging are posing unprecedented challenges in sustaining the health of 9.1 billion people that will be occupying the planet by 2050. Although noncommunicable diseases such as cardiovascular and neurodegenerative diseases, cancer, and diabetes are among the top 10 global causes of death, they can be prevented by risk factor reduction, early detection, and adequate treatment. Since a healthy diet along with dietary supplementation could play an important role to reduce morbidity and cut off its associated health care costs, research in the food and nutrition area is required to find solutions to global challenges affecting health. As a result of the healthy living trend, dietary supplements category is growing fast, leading to an urgent need for dietitians, physicians, and policy makers to broaden the scientific evidence on the efficacy and safety of a wide range of active ingredients. Coenzyme Q10 (CoQ10), as the third most consumed dietary supplement, and as a potential candidate for the treatment of various noncommunicable diseases that are among the global top 10 causes of death, has gained interest over years. Scientific evidence regarding mainly CoQ10 efficacy and safety, as well as formulation challenges, is addressed in this review.

show abstract

Section: Coq10 Supplementationmentioning

confidence: 99%

Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges

Arenas-Jal

Suñé-Negre

García-Montoya

2020

Comp Rev Food Sci Food Safe

102

View full text Add to dashboard Cite

show abstract

“…The ubidecarenone is a coenzyme related to mitochondrial enzyme complexes and involved in oxidative phosphorylation in the production of ATP, which is sold as a dietary supplement and is not FDA approved as a drug, however, it is recommended to be used under discretion. For pharmacology, coenzyme Q10 was studied to use for treating of several diseases, e.g., Parkinson's [39], fibromyalgia [40,41], migraine [42,43], and periodontal disease [44,45]. DB00756 or Hexachlorophene is a bacteriostatic cleansing agent.…”

Section: Potential Targets Of Succinate Dehydrogenase Complexmentioning

confidence: 99%

Heterogeneous Network Model to Identify Potential Associations Between Plasmodium vivax and Human Proteins

Suratanee

Plaimas

2020

IJMS

View full text Add to dashboard Cite

Integration of multiple sources and data levels provides a great insight into the complex associations between human and malaria systems. In this study, a meta-analysis framework was developed based on a heterogeneous network model for integrating human-malaria protein similarities, a human protein interaction network, and a Plasmodium vivax protein interaction network. An iterative network propagation was performed on the heterogeneous network until we obtained stabilized weights. The association scores were calculated for qualifying a novel potential human-malaria protein association. This method provided a better performance compared to random experiments. After that, the stabilized network was clustered into association modules. The potential association candidates were then thoroughly analyzed by statistical enrichment analysis with protein complexes and known drug targets. The most promising target proteins were the succinate dehydrogenase protein complex in the human citrate (TCA) cycle pathway and the nicotinic acetylcholine receptor in the human central nervous system. Promising associations and potential drug targets were also provided for further studies and designs in therapeutic approaches for malaria at a systematic level. In conclusion, this method is efficient to identify new human-malaria protein associations and can be generalized to infer other types of association studies to further advance biomedical science.

show abstract

“…This means it is not useful for compounds that are metabolically based, such as coenzyme Q10 (CoQ10) or creatine, which have been studied. 16,17 These compounds would not be expected to impact motor symptoms but to impact progression.…”

Section: Dr Rountree: Does That Mean No One Should Eat Dairy?mentioning

confidence: 99%

“…Like CoQ0 and creatine, the answer to those studies has been no. 16,17 They have all failed, even though there was evidence to support them up until the Phase III trial. At some point, you have to step back and wonder whether we are designing the trials wrong.…”

Section: Dr Mischleymentioning

confidence: 99%